Short Interest in bioMerieux (OTCMKTS:BMXMF) Declines By 42.6%

bioMerieux (OTCMKTS:BMXMF) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 75,449 shares, a decrease of 42.6% from the April 15th total of 131,417 shares. Based on an average daily trading volume, of 260 shares, the days-to-cover ratio is presently 290.2 days. Currently, 0.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BMXMF. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Finally, BNP Paribas Exane lowered shares of bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

bioMerieux Stock Down 0.5%

BMXMF stock opened at $84.00 on Friday. The company’s 50 day simple moving average is $102.04 and its 200-day simple moving average is $115.34. bioMerieux has a 12 month low of $77.38 and a 12 month high of $152.00. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.